A. S. Go, E. M. Hylek, and K. A. Phillips, Prevalence of Diagnosed Atrial Fibrillation in Adults, JAMA, vol.285, issue.18, pp.285-2370, 2001.
DOI : 10.1001/jama.285.18.2370

K. Bon-usage-des-médicaments-antivitamine, En ligne] Disponible sur : http://ansm.sante.fr/var/ansm_site/storage/original/application

H. Autorité and D. Santé, Evaluation de l'autosurveillance de l'INR chez les patients adultes traités par antivitamine K. [En ligne] Disponible sur : http://www.hassante.fr/portail

M. Badal, M. R. Aryal, and J. Mege, Evaluation of Trends of Inpatient Hospitalisation for Significant Haemorrhage in Patients Anticoagulated for Atrial Fibrillation before and after the Release of Novel Anticoagulants, Heart, Lung and Circulation, vol.24, issue.1, pp.24-94, 2015.
DOI : 10.1016/j.hlc.2014.06.013

C. Stöllberger and J. Finsterer, Reservations against new oral anticoagulants after stroke and cerebral bleeding, Journal of the Neurological Sciences, vol.330, issue.1-2, pp.16-17, 2013.
DOI : 10.1016/j.jns.2013.03.017

M. Crowther and M. A. Crowther, Antidotes for Novel Oral Anticoagulants Current Status and Future Potential

H. Autorité and D. Santé, Surdosage en AVK, situations à risque et accidents hémorragiques ? Recommandations. [En ligne] Disponible sur : http://www.hassante.fr/portail/jcms/c_682188/prise-en-charge-des-surdosages-des-situations-a-risque- hemorragique-et-desaccidents-hemorragiques-chez-les-patients-traites-par-antivitaminesk-en-ville-et-en-milieu-hospitalier

R. Altman and C. Gonzalez, Simple and rapid assay for effect of the new oral anticoagulant (NOAC) rivaroxaban: preliminary results support further tests with all NOACs, Thrombosis Journal, vol.12, issue.1, p.12, 2014.
DOI : 10.1161/CIRCULATIONAHA.113.004747

. Groupe-d-'intérêt-en-hémostase-périopératoire, Gestion périopératoire des anticoagulants oraux directs. [En ligne] Disponible sur : http://sofia.medicalistes.org/spip

D. Khadzhynov, F. Wagner, and S. Formella, Effective elimination of dabigatran by haemodialysis, Thrombosis and Haemostasis, vol.109, issue.4, pp.596-605
DOI : 10.1160/TH12-08-0573

D. M. Siegal and A. Cuker, Reversal of novel oral anticoagulants in patients with major bleeding, Journal of Thrombosis and Thrombolysis, vol.109, issue.6, pp.35-391
DOI : 10.1002/14651858.CD001886.pub4

M. M. Levi, E. Eerenberg, and E. Lowenberg, Bleeding in patients using new anticoagulants or antiplatelet agents: risk factors and management, Netherlands Journal of Medicine, issue.2, pp.68-68, 2010.

A. Majeed and S. Schulman, Bleeding and antidotes in new oral anticoagulants. Best Practice & Research Clinical Haematology, pp.191-202, 2013.

A. Liew, J. W. Eikelboom, and M. Donnell, Assessment of Anticoagulation Intensity and Management of Bleeding With Old and New Oral Anticoagulants, Canadian Journal of Cardiology, vol.29, issue.7, pp.29-34, 2013.
DOI : 10.1016/j.cjca.2013.04.013

R. S. Kazmi and B. A. Lwaleed, New anticoagulants: how to deal with treatment failure and bleeding complications, British Journal of Clinical Pharmacology, vol.62, issue.2, pp.593-603, 2011.
DOI : 10.1111/j.1365-2044.2007.05195.x

D. M. Siegal, Managing target-specific oral anticoagulant associated bleeding including an update on pharmacological reversal agents, Journal of Thrombosis and Thrombolysis, vol.35, issue.3, pp.39-395
DOI : 10.1007/s11239-013-0885-0

L. M. Baumann-kreuziger, J. C. Keenan, and C. T. Morton, Management of the Bleeding Patient Receiving New Oral Anticoagulants: A Role for Prothrombin Complex Concentrates, BioMed Research International, vol.116, issue.183, p.2014
DOI : 10.1177/1076029613494468

E. S. Eerenberg, P. W. Kamphuisen, and M. K. Sijpkens, Reversal of Rivaroxaban and Dabigatran by Prothrombin Complex Concentrate: A Randomized, Placebo-Controlled, Crossover Study in Healthy Subjects, Circulation, vol.124, issue.14, pp.124-1573, 2011.
DOI : 10.1161/CIRCULATIONAHA.111.029017

D. Caldeira, M. Barra, and F. J. Pinto, Intracranial hemorrhage risk with the new oral anticoagulants: a systematic review and meta-analysis, Journal of Neurology, vol.33, issue.2104
DOI : 10.1002/phar.1269

D. J. Gladstone, E. Bui, and J. Fang, Potentially Preventable Strokes in High-Risk Patients With Atrial Fibrillation Who Are Not Adequately Anticoagulated, Stroke, vol.40, issue.1
DOI : 10.1161/STROKEAHA.108.516344

P. Nardo, D. Shah, and H. Burri, Fibrillation auriculaire. [En ligne] Disponible sur : http://www.hugge .ch/sites/interhug/files/structures/medecine_de_premier_recours/documents, 2015.

A. J. Camm, P. Kirchhof, and G. Y. Lip, Guidelines for the management of atrial fibrillation, European heart journal, issue.19, pp.31-2369, 2010.

P. Kirchhof, A. Auricchio, and J. Bax, Outcome parameters for trials in atrial fibrillation

H. The, Score Identifies Patients with Acute Venous Thromboembolism at High Risk of Major Bleeding Complications during the First Six Months of Anticoagulant Treatment, Public Library of Science one, vol.10, issue.4, 2015.

B. F. Gage, Y. Yan, and P. E. Milligan, Clinical classification schemes for predicting hemorrhage: Results from the National Registry of Atrial Fibrillation (NRAF), American Heart Journal, vol.151, issue.3
DOI : 10.1016/j.ahj.2005.04.017

S. Apostolakis, D. A. Lane, and Y. Guo, Performance of the HEMORR2HAGES, ATRIA, and HAS-BLED Bleeding Risk???Prediction Scores in Patients With Atrial Fibrillation Undergoing Anticoagulation, Journal of the American College of Cardiology, vol.60, issue.9, pp.60-861
DOI : 10.1016/j.jacc.2012.06.019

D. E. Singer, Y. Chang, and M. C. Fang, et al The net clinical benefit of warfarin anticoagulation in atrial fibrillation, Annals of internal medicine, issue.5, pp.151-297, 2009.

T. Vogel, B. Geny, and G. Kaltenbach, et al Anticoagulation de la fibrillation atriale par les nouveaux anticoagulants chez la personne âgée : les limites de « l'Evidence-Based Medicine

G. Bouvenot, J. Bounhoure, and J. Montastruc, Rapport sur les anticoagulants oraux directs (AOD). [En ligne] Disponible sur : http://www.academie-medecine, 2014.

S. J. Connolly, M. D. Ezekowitz, and S. Yusuf, Dabigatran versus Warfarin in Patients with Atrial Fibrillation, New England Journal of Medicine, vol.361, issue.12
DOI : 10.1056/NEJMoa0905561

J. Desai, C. B. Granger, and J. I. Weitz, Novel oral anticoagulants in gastroenterology practice, Gastrointestinal Endoscopy, vol.78, issue.2, pp.78-227, 2013.
DOI : 10.1016/j.gie.2013.04.179

K. Uchino and A. Hernandez, Dabigatran Association With Higher Risk of Acute Coronary Events, Archives of Internal Medicine, vol.172, issue.5, pp.172-397, 2012.
DOI : 10.1001/archinternmed.2011.1666

P. Harper, L. Young, and E. Merriman, Bleeding Risk with Dabigatran in the Frail Elderly, New England Journal of Medicine, vol.366, issue.9
DOI : 10.1056/NEJMc1112874

. Cardiologie-francophone, Prise en charge de la fibrillation auriculaire : recommandations ESC 2010 et 2012. [En ligne] Disponible sur

N. J. Veeger, M. Piersma?wichers, and K. Meijer, Minor bleeds alert for subsequent major bleeding in patients using vitamin K antagonists, British Journal of Haematology, vol.24, issue.4, pp.508-514, 2011.
DOI : 10.1592/phco.24.14.1311.43144

URL : https://hal.archives-ouvertes.fr/hal-00625169

A. J. Camm, G. Y. Lip, and R. De-caterina, focused update of the ESC Guidelines for the management of atrial fibrillation, European heart journal, issue.21, pp.33-2719, 2012.

I. Serghini, Y. Aissaoui, and Y. Quamouss, Accidents to AVK: a retrospective study of 30 cases, Pan African medical journal, issue.11, p.24, 2011.

I. L. Holster, V. E. Valkhoff, and E. J. Kuipers, New Oral Anticoagulants Increase Risk for Gastrointestinal Bleeding: A Systematic Review and Meta-analysis, Gastroenterology, vol.145, issue.1
DOI : 10.1053/j.gastro.2013.02.041

I. L. Holster, N. G. Hunfeld, and E. J. Kuipers, On the treatment of new oral anticoagulant-associated gastrointestinal hemorrhage, Journal of Gastrointestinal and Liver Diseases, vol.22, pp.229-231, 2013.

T. Steiner, J. Rosand, and M. Diringer, Intracerebral Hemorrhage Associated With Oral Anticoagulant Therapy: Current Practices and Unresolved Questions, Stroke, vol.37, issue.1
DOI : 10.1161/01.STR.0000196989.09900.f8

URL : http://stroke.ahajournals.org/content/strokeaha/37/1/256.full.pdf

M. K. Kasliwal, N. G. Panos, and L. F. Munoz, Outcome following intracranial hemorrhage associated with novel oral anticoagulants, Journal of Clinical Neuroscience, vol.22, issue.1, pp.212-215, 2015.
DOI : 10.1016/j.jocn.2014.04.025

J. Hagii, H. Tomita, and N. Metoki, Characteristics of Intracerebral Hemorrhage During Rivaroxaban Treatment Comparison With Those During Warfarin

U. A. Flato, P. S. Rheder, and H. P. Guimarães, Spine subdural hematoma: a rare complication associated with vitamin K antagonist (VKA)

P. Olivier, J. Caron, and F. Haramburu, Validation of a measurement scale: example of a French Adverse Drug Reactions Preventability Scale

W. Manatsathit, H. Al-hamid, and P. Leelasinjaroen, Management of gastrointestinal bleeding in patients anticoagulated with dabigatran compared with warfarin: a retrospective, comparative case review. Cardiovascular diagnosis and therapy, p.224

G. Pernod, P. Albaladejo, and A. Godier, Management of major bleeding complications and emergency surgery in patients on longterm treatment with direct oral anticoagulants, thrombin or factor-Xa inhibitors: proposals of the working group on perioperative haemostasis, Archives of cardiovascular diseases, issue.6, pp.106-382, 2013.

R. Marlu, E. Hodaj, and A. Paris, Effect of non-specific reversal agents on anticoagulant activity of dabigatran and rivaroxaban, Thrombosis and Haemostasis, vol.108, issue.2, pp.217-224
DOI : 10.1160/TH12-03-0179

C. T. Ruff, R. P. Giugliano, and E. Braunwald, Comparison of the efficacy and safety of new oral anticoagulants with warfarin in patients with atrial fibrillation: a meta-analysis of randomised trials, The Lancet, vol.383, issue.9921, pp.383-955, 2014.
DOI : 10.1016/S0140-6736(13)62343-0

URL : https://hal.archives-ouvertes.fr/hal-00935589

M. Forsblad, J. Wieloch, and M. , Étude " en vie réelle du bénéfice/risque à court terme des nouveaux anticoagulants oraux (dabigatran, rivaroxaban) chez les patients débutant un traitement et non précédemment traités par des antivitamines K Étude NACORA-BR du projet NACORA (nouveaux anticoagulants oraux et risques associés) [En ligne] Disponible sur : http://ansm.sante.fr/content/download Bleeding complications related to warfarin treatment: a descriptive register study from the anticoagulation clinic at Helsingborg Hospital, Caisse Nationale de l'Assurance Maladie des Travailleurs Salariés (CNAMTS), pp.38-98, 828917.

A. Gómez-outes, A. I. Terleira-fernández, and G. Calvo-rojas, Dabigatran, Rivaroxaban, or Apixaban versus Warfarin in Patients with Nonvalvular Atrial Fibrillation: A Systematic Review and Meta-Analysis of Subgroups, Thrombosis, vol.126, issue.19, p.2013
DOI : 10.1016/S0140-6736(11)61294-4

S. K. Kakkos, G. I. Kirkilesis, and I. A. Tsolakis, Editor's Choice - Efficacy and Safety of the New Oral Anticoagulants Dabigatran, Rivaroxaban, Apixaban, and Edoxaban in the Treatment and Secondary Prevention of Venous Thromboembolism: A Systematic Review and Meta-analysis of Phase III Trials, European Journal of Vascular and Endovascular Surgery, vol.48, issue.5, pp.565-575
DOI : 10.1016/j.ejvs.2014.05.001

M. D. Wallentin, L. Connolly, and S. J. , Meta-analysis of randomized controlled trials on the risk of bleeding with dabigatran Dabigatran and warfarin in vitamin K antagonist?naive and?experienced cohorts with atrial fibrillation, American journal of cardiology Circulation, vol.113, issue.622, pp.1066-1074, 2010.

J. A. Vílchez, P. Gallego, and G. Lip, Safety of new oral anticoagulant drugs: a perspective. Therapeutic advances in drug safety, pp.8-20, 2013.

D. J. Graham, M. E. Reichman, and M. Wernecke, Cardiovascular, bleeding, and mortality risks in elderly medicare patients treated with dabigatran or warfarin for non-valvular atrial fibrillation, Circulation, issue.2, pp.131-157, 2014.

T. B. Larsen, L. H. Rasmussen, and F. Skjøth, Efficacy and Safety of Dabigatran Etexilate and Warfarin in ???Real-World??? Patients With Atrial Fibrillation, Journal of the American College of Cardiology, vol.61, issue.22, pp.61-2264, 2013.
DOI : 10.1016/j.jacc.2013.03.020